Spots Global Cancer Trial Database for primary refractory neuroblastoma
Every month we try and update this database with for primary refractory neuroblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients | NCT00969722 | Primary Refract... | MAb-3F8 Subcutaneous Gr... 13-cis-Retinoic... | 18 Months - 13 Years | United Therapeutics | |
| A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients | NCT00969722 | Primary Refract... | MAb-3F8 Subcutaneous Gr... 13-cis-Retinoic... | 18 Months - 13 Years | United Therapeutics | |
| A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients | NCT00969722 | Primary Refract... | MAb-3F8 Subcutaneous Gr... 13-cis-Retinoic... | 18 Months - 13 Years | United Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
